Sovateltide for adults with a recent spinal cord injury
Tests sovateltide against saline in adults with a recent spinal cord injury.
Key facts
- Who runs it
- Pharmazz, Inc.
- Where
- India5 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT04054414
- CTRI/2018/12/016667
- Registry title
- PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 10 Jan 2019
- Planned end
- Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Normal Saline along with standard treatment
- PMZ-1620 along with standard treatment
- Record updated
- 4 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent, partial spinal cord injury. They can receive the study drug PMZ-1620 or saline within 48 hours of the injury.
- Age
- 18 to 75 years
- Sex
- Men and women
- Disease stage
- Acute, incomplete spinal cord injury: ISNCSCI grade "B", "C" or "D". Injury level C5-C8, T1-T12, L1-L5 or S1-S5. Partial damage shown on CT or MRI scan.
- Earlier treatment
- Cannot be using drugs that weaken the immune system or cancer chemotherapy drugs.
Main reasons for not taking part
- Complete injury (grade "A"), or needing a breathing machine (ventilator)
- Earlier spinal cord disease, or a spine fracture caused by disease
- Serious head injury seen on head CT
- Pregnant or breastfeeding, or BMI of ≥35 kg/m2
- Weak immune system including HIV, rheumatoid arthritis, serious heart problems, or brain disorders like Alzheimer's or Parkinson's
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Adult males or females aged between 18 and 75 years inclusive
- Able to give consent for participation on their own or through their Legally Acceptable Representative (LAR)
- Able to cooperate in the completion of a standardized neurological examination by ISNCSCI standards (excludes patients who are on ventilator)
- ISNCSCI Impairment Scale Grade "B," "C" or "D" based upon first ISNCSCI evaluation after arrival to the hospital is classified as motor or sensory incomplete
- Willing and able to comply with the study Protocol
- Women must be of non-childbearing potential or surgically sterile or willing to use adequate birth control; men who are sexually active will also be required to use adequate birth control
- Able to receive the Investigational Drug within 48 hours of injury
- Neurological Level of Injury between C5-C8, T1-T12, L1-L5 and S1-S5 based upon first ISNCSCI evaluation after arrival to the hospital
- Patient with incomplete/partial damage/transaction as shown by CT or MRI scan
- Patients with any other chronic conditions, who are stable with appropriate treatment
Who cannot take part
- Previous history related to spinal cord disease
- Concomitant head injury with a clinically significant abnormality on a head CT (head CT required only for patients suspected to have a brain injury at the discretion of the investigator)
- Patients who are currently participating in a clinical trial with an investigational drug or investigational device
- Impairment Scale Grade "A" based upon first ISNCSCI assessment and classified as complete injury
- Known immunodeficiency, including human immunodeficiency virus, or use of immunosuppressive or cancer chemotherapeutic drugs
- The participant has a clinically significant cardiovascular disorder or an abnormal electrocardiogram (ECG) at the discretion of the investigator
- Pre-existent neurologic disorder which would preclude accurate evaluation and follow-up (i.e. Alzheimer's disease, Parkinson's disease, any psychiatric disorder with hallucinations/delusions/schizophrenia)
- Patient on ventilator or requires ventilator
- Patient with pathological fracture of vertebral column
- One or more upper extremity muscle groups un-testable during baseline ISNCSCI examination
- Females who are breastfeeding or have a positive urine pregnancy test
- Body mass index (BMI) of ≥35 kg/m2 at screening
- Patient having rheumatoid arthritis
- Patients who, in the opinion of the investigator, are otherwise unsuitable for this study
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute spinal cord injury.
The 2 groups in the trial
- Normal SalineExisting treatment, for comparison
Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
Treatment: Normal Saline along with standard treatment
- PMZ-1620Treatment being tested
Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
Treatment: PMZ-1620 along with standard treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicentric, Randomized, Double Blind, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Patients of Acute Spinal Cord Injury
- Plain-language title
- Sovateltide for adults with a recent spinal cord injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT04054414, who can take part
- Record updated
- 4 July 2025